Scientech Research LLC Buys 868 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Scientech Research LLC lifted its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 12.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,769 shares of the medical device company’s stock after buying an additional 868 shares during the period. Scientech Research LLC’s holdings in Cooper Companies were worth $678,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in COO. Benjamin F. Edwards & Company Inc. lifted its stake in shares of Cooper Companies by 248.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 244 shares of the medical device company’s stock valued at $25,000 after buying an additional 174 shares during the period. Innealta Capital LLC bought a new position in Cooper Companies during the second quarter worth about $25,000. Covestor Ltd lifted its stake in Cooper Companies by 305.9% during the first quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock worth $28,000 after purchasing an additional 208 shares during the period. Crewe Advisors LLC lifted its stake in Cooper Companies by 286.4% during the second quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock worth $30,000 after purchasing an additional 252 shares during the period. Finally, Tortoise Investment Management LLC lifted its stake in Cooper Companies by 75.4% during the second quarter. Tortoise Investment Management LLC now owns 393 shares of the medical device company’s stock worth $34,000 after purchasing an additional 169 shares during the period. Institutional investors own 24.39% of the company’s stock.

Insider Buying and Selling at Cooper Companies

In other Cooper Companies news, CEO Albert G. White III sold 114,992 shares of the stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $110.53, for a total value of $12,710,065.76. Following the transaction, the chief executive officer now directly owns 165,273 shares of the company’s stock, valued at approximately $18,267,624.69. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CAO Agostino Ricupati sold 1,601 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $108.03, for a total transaction of $172,956.03. Following the transaction, the chief accounting officer now directly owns 4,818 shares of the company’s stock, valued at $520,488.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Albert G. White III sold 114,992 shares of the firm’s stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the transaction, the chief executive officer now directly owns 165,273 shares in the company, valued at $18,267,624.69. The disclosure for this sale can be found here. Insiders have sold a total of 256,373 shares of company stock valued at $27,637,427 in the last three months. 2.00% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

COO has been the subject of a number of analyst reports. Piper Sandler raised their price target on shares of Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, August 29th. Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a research note on Thursday, August 29th. Morgan Stanley raised their price target on shares of Cooper Companies from $95.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Tuesday, September 10th. Wells Fargo & Company lifted their target price on shares of Cooper Companies from $110.00 to $115.00 and gave the company an “overweight” rating in a research note on Thursday, August 29th. Finally, Robert W. Baird boosted their target price on Cooper Companies from $118.00 to $125.00 and gave the stock an “outperform” rating in a report on Thursday, August 29th. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $115.00.

Cooper Companies Stock Up 0.2 %

Shares of COO stock opened at $109.78 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.18 and a current ratio of 1.99. The firm’s 50-day moving average is $99.84 and its 200-day moving average is $95.77. The stock has a market cap of $21.86 billion, a price-to-earnings ratio of 64.58, a PEG ratio of 2.63 and a beta of 0.98. The Cooper Companies, Inc. has a 52-week low of $75.93 and a 52-week high of $112.38.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.91 by $0.05. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $997.30 million. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The business’s revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.84 EPS. Sell-side analysts predict that The Cooper Companies, Inc. will post 3.65 EPS for the current year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.